FIDSON HEALTHCARE PLC hereby announces as follows:
Period Ended
31st December 2022.
A Final Dividend of 55 kobo per 50 kobo ordinary share, subject to appropriate
withholding tax and approval will be paid to shareholders whose names appear in
Proposed Dividend
the Register of Members at the close of business on Friday , 7th of July 2023.
Proposed Bonus
NIL
The Register of Shareholders will be closed from Monday, the 10th to Friday 14th of
Closure of Register
July 2023.
Qualification Date
Friday, 7th of July 2023.
Dividends will be paid 24 hours after the Annual General Meeting. The date of the
Payment Date
AGM is to be advised.
Shareholders who are yet to complete the e-dividend registration are advised to
download the Registrar's E-DividendMandate Activation Form, which is also
available on the website of Meristem Registrars and Probate Limited, complete
E-Dividend Registration
and submit it to the Registrar or their respective Banks.
Unclaimed
Dividend
Shareholders with dividend warrants and share certificates that have remained
Warrants
and
Share
unclaimed or are yet to be presented for payment or returned for validation are
Certificates
advised to complete the e-dividend registration or contact the Registrar.
Date of
Annual
General
Meeting
To be advised.
Meristem Registrar and Probate Limited.
213 Herbert Macaulay Way, Adekunle - Yaba, Lagos.
Tel: 234 1 8920491
Registrar
Email:info@meristemregistrars.com
Mr. Imokha Ayebae, imokhaayebae@fidson.com, 0703 402 3848
Investor Relations
Mr. Yomi Adebanjo, yomiadebanjo@fidson.com, 0802 314 6760
J. A. Adebanjo, FCIS
Company Secretary.
Dated this 31st March 2023.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Fidson Healthcare plc published this content on 01 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 April 2023 17:08:07 UTC.
Fidson Healthcare specializes in developing, manufacturing and marketing pharmaceutical products for the treatment of infectious, inflammatory, endocrinal, gastrointestinal, immune, metabolic, cardiovascular, oncological and central nervous system disorders. Net sales break down by activity as follows:
- sale of prescription medicines (70.7%) ;
- sale of OTC products (29.3%).